Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

B Cell Design is a biotechnology company which develops innovative products and breakthrough therapeutic concepts for pharma industries. B Cell Design manufactures through its technological platform and its expertise a portfolio of solutions for in vitro diagnostic companies.Based in Limoges, B Cell Design built strong partnerships with international in vitro diagnostic and pharmaceutical companies.

Seikagaku Corp. manufactures pharmaceuticals and medical devices with glycoconjugates; specifically, glycosaminoglycans (GAG) such as hyaluronic acid; as well as enzymes that act on GAG. It operates through the following segments: Pharmaceuticals and Limulus Amebocyte Lysate (LAL). The Pharmaceuticals segment develops and supplies intra-articular injections for improving joint functions, cross-linked hyaluronate hydrogel for knee osteoarthritis, opthalmic surgical aids, and surgical aids for endoscopic mucosal resection. The LAL segment manufactures and sells endotoxin-detecting reagents in Japan and overseas. The company was founded on June 2, 1947 and is headquartered in Tokyo, Japan.

Shanghai Runpu Biotechnology Co., Ltd., established on 2010-11-16, Business scope includes general items:Technical services in the field of biomedicine,technical consulting(human stem cells,Except for the development and application of genetic diagnosis and treatment technology),Production and sales of Class I medical devices,Sales of Class II Medical Devices,Own Equipment Rental(Not to engage in financial leasing),medical consultation(Do not engage in medical activities),Health Management Consulting(Do not engage in medical activities,psychological counseling),Business Consulting(Does not include investment consulting),Own house rental,Warehousing Services(Removal of hazardous chemicals),Disinfectant sales(Free of Hazardous Chemicals),Sales of rubber and plastic products,computer software sales,Wholesale of cosmetics,retail.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license) licensed items:Disinfectant production(Free of Hazardous Chemicals);Technology Import and Export;Import and export;Production of Class III Medical Devices;Production of Class II Medical Devices;Cosmetic production;Class III medical device business.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)

Hayashibara Biochemical Laboratories, Inc. manufactures food and cosmetic products. It also makes health food ingredients, functional dyes, and reagents. The company was founded in 1970 and is headquartered in Okayamashi, Japan.

Institut Mérieux SA provides solutions for multifactorial management of diseases. The firm provides solutions for diseases, including tuberculosis, liver cancer and hepatitis. It specializes in the field human and veterinary of vaccines. It operates under the activities of diagnostics, immunotherapy and nutrition. The company was founded by Marcel Mérieux in 1897 and is headquartered Lyon, France.

Yamanouchi Pharmaceutical Co. Ltd. manufactures and markets drugs, quasi-drugs and medical devices. It used to promote collaboration with other pharmaceutical companies as well as bioventure companies and academia to raise the quality and speed of its R&D activities. It was founded in 1923. The company was headquartered in Tokyo, JP

Kissei Pharmaceutical Co., Ltd. engages in the research, development, manufacture and sale of pharmaceutical products and health foods. It operates through the following segments: Pharmaceuticals, Information Service, and Others. The Pharmaceuticals segment researches, develops, manufactures, and markets drugs, which are used in the fields of urology, dialysis, women's health, ophthalmology, endocrinology and metabolism. The Information Service segment offers information services to use in IT and capital investment. The Others segment includes merchandise sales and construction contractors. The company was founded on August 9, 1946 and is headquartered in Matsumoto, Japan.

As of May 28, 2009, Avalon Pharmaceuticals, Inc. was acquired by Clinical Data, Inc. Avalon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of cancer therapeutics using its proprietary AvalonRx technology in the United States. The company’s lead product candidate, AVN944, an inosine monophosphate dehydrogenase (IMPDH) inhibitor, is in Phase IIa clinical development for the treatment of hematologic and solid cancers. Avalon Pharmaceuticals has drug discovery, development, and commercialization agreement with Merck & Co., Inc. to identify and develop inhibitors against a selected target in the area of oncology; a collaboration and license agreement with MedImmune, Inc. for the discovery of small molecule therapeutic compounds in the area of inflammatory disease; a collaboration agreement with ChemDiv, Inc. for the discovery and development of small molecule oncology therapeutics; a collaboration with Medarex, Inc. to jointly research, develop, and commercialize human antibodies against the company’s cancer targets; and an agreement with Novartis Institutes for Biomedical Research, Inc. for the discovery of small molecule therapeutic compounds. The company was incorporated in 1999 and is headquartered in Germantown, Maryland.

Autobio Diagnostics is a company mainly engaged in development, manufacture and sales of diagnostics products.

Fujirebio, Inc. engages in the manufacture, sale, import and export of clinical diagnostic reagents and assay instruments. It also provides diagnostic, clinical laboratory testing and related services. The company was founded on December 18, 1950 and is headquartered in Tokyo, Japan.

Guangdong Ruiqi Biotechnology Co., Ltd., established on 2017-05-12, The scope of business includes engaging in biotechnology,Technology research and development in the field of medical equipment and computer software,technical consulting,Technical Services,technology transfer;wholesale,retail:medical supplies,medical instruments,Laboratory equipment and scientific research products(Operating with a valid operating license);Import and export,Technology Import and Export.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments.)(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Acceleron Pharma, Inc. operates as a biopharmaceutical company. The company engages in developing, manufacturing, and commercializing novel biotherapeutics that modulate the growth of bone, muscle, fat, and the vasculature to treat musculoskeletal, metabolic, and cancer-related diseases. Its products include ACE-011 Program, a novel bone forming agent that helps to treat cancer-related bone loss; ACE-031 Program that helps to treat diseases involving the loss of muscle mass, strength, and function in diseases, including muscular dystrophy, amyotrophic lateral sclerosis, and cancer-related muscle loss; and ACE-041, a protein therapeutic that binds a member of the growth and differentiation factor family necessary for angiogenesis. It develops therapies based on growth and differentiation factors that regulate the cellular proliferation, differentiation, and survival of a range of tissue types. The company offers treatments for cancer-related bone loss, cancer-related muscle loss, neuromuscular diseases, and metabolic disorders. Acceleron Pharma, Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.

Libo Pharmaceuticals engages in the R&D, production, and sales of HLA molecular biology and tumor detection and other related products. Together with Wuxi Yuanbo Biotechnology Co., Ltd., a wholly-owned subsidiary focusing on the research and development, and production of clinical testing instruments, we are committed to becoming a professional supplier and service provider of domestic clinical testing reagents and testing instruments, providing comprehensive solutions for clinical testing institutions. The company was founded in 2007 and is based in Jiangsu Province, China.

Kemei Boyang Diagnostic Technology (Shanghai) Co., Ltd., established on 2005-08-17, Business scope includes general items:Diagnostic Technology,medical technology,Biological Technology(human stem cells,Except for the development and application of genetic diagnosis and treatment technology)technical services in the field,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Biological product,Chemical products and raw materials(Removal of hazardous chemicals,Monitor Chemicals,civilian explosives,precursor chemicals)research and development;Specialty Chemicals Sales(Free of Hazardous Chemicals);Production of Class I Medical Devices;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Own Equipment Rental;Import and export;Technology Import and Export.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license) licensed items:Production of Class II Medical Devices;Production of Class III Medical Devices;Class III medical device business.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)

Engages in research and development of biological products

Beijing Boshengfu Biotechnology Co., Ltd., established on 2007-04-19, Business scope includes technology development,technology transfer,technical consulting,Technical Services.(Enterprises independently choose operating projects according to law,Carry out business activities;Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the city's industrial policies.)